Patents Assigned to Nutramax Laboratories, Inc.
  • Patent number: 11752123
    Abstract: An anxiolytic composition includes a synergistic combination of one or more of an L-theanine, an s-adenosylmethionine (SAMe), and optionally an extract of Magnolia, an extract of Phellodendron, and a whey protein.
    Type: Grant
    Filed: January 25, 2021
    Date of Patent: September 12, 2023
    Assignee: NUTRAMAX LABORATORIES, INC.
    Inventors: Todd Henderson, David Griffin, David Bledsoe
  • Patent number: 11654186
    Abstract: The present disclosure relates to the synergistic combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, a cofactor of the enzyme, and a glucan. The present disclosure also relates to the synergistic combination of sulforaphane or a derivative thereof and a glucan. The present disclosure also relates to the synergistic combination of a broccoli extract or powder and a glucan. The glucan may be a ?-glucan. The glucan may be provided in a mushroom extract or powder selected from one or more of a maitake, a shiitake, or a reishi mushroom. Compositions and methods relating to these combinations are described.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: May 23, 2023
    Assignee: Nutramax Laboratories, Inc.
    Inventors: Brian Cornblatt, Grace Cornblatt, Anton Bzhelyansky, Robert Henderson
  • Publication number: 20220362172
    Abstract: The present application relates to compositions comprising avocado/soybean unsaponifiables (“ASU”) and cannabis, and related methods of use. In one embodiment, the cannabis is a cannabis oil extract that is combined with ASU to reduce inflammatory responses and inflammation in humans and animals.
    Type: Application
    Filed: July 27, 2022
    Publication date: November 17, 2022
    Applicant: NUTRAMAX LABORATORIES, INC.
    Inventors: Todd R. Henderson, David Griffin
  • Patent number: 11426363
    Abstract: The present application relates to compositions comprising avocado/soybean unsaponifiables (“ASU”) and cannabis, and related methods of use. In one embodiment, the cannabis is a cannabis oil extract that is combined with ASU to reduce inflammatory responses and inflammation in humans and animals.
    Type: Grant
    Filed: July 16, 2020
    Date of Patent: August 30, 2022
    Assignee: NUTRAMAX LABORATORIES, INC.
    Inventors: Todd R. Henderson, David Griffin
  • Patent number: 11419848
    Abstract: The present invention relates to a composition for the protection, treatment and repair of cartilage in humans and animal joints. The composition contains a combination of unsaponifiable lipids together with one or more of polyphenols and/or catechins. The composition or kit may contain avocado:soybean unsaponifiables (ASU) and green tea.
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: August 23, 2022
    Assignee: NUTRAMAX LABORATORIES, INC.
    Inventors: Todd R. Henderson, Louis Lippiello, Charles Filburn, David Griffin
  • Publication number: 20220110946
    Abstract: Compositions are described including a synergistic combination of hydroxytyrosol and 3-O-acetyl-11-keto-?-boswellic acid. The hydroxytyrosol may be sourced from an olive extract and the 3-O-acetyl-11-keto-?-boswellic acid may be sourced from a Boswellia serrata extract. The compositions may be formulated for oral administration to a mammalian or an avian subject. Methods for treating, repairing, or reducing damage to connective tissue caused by one or more inflammatory mediators and for reducing levels of one or more inflammatory mediators in connective tissue are provided, the methods comprising orally administering the compositions to a subject in need thereof.
    Type: Application
    Filed: December 22, 2021
    Publication date: April 14, 2022
    Applicant: NUTRAMAX LABORATORIES, INC.
    Inventors: Todd Henderson, David Griffin
  • Patent number: 11241444
    Abstract: Compositions are described including a combination of hydroxytyrosol and 3-O-acetyl-11-keto-?-boswellic acid. The hydroxytyrosol may be sourced from an olive extract and the 3-O-acetyl-11-keto-?-boswellic acid may be sourced from a Boswellia serrata extract. The compositions may be formulated for oral administration to a mammalian or an avian subject. Methods for preventing or reducing an inflammatory response in connective tissue are provided, the methods comprising orally administering the compositions to a subject in need thereof.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: February 8, 2022
    Assignee: Nutramax Laboratories, Inc.
    Inventors: Todd Henderson, David Griffin
  • Patent number: 11224639
    Abstract: The invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and a milk thistle extract or powder. The invention also relates to the combination of a sulforaphane or a derivative thereof and a milk thistle extract or powder. The invention also relates to the combination of a broccoli extract or powder and a milk thistle extract or powder. The invention provides compositions and methods relating to these combinations.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: January 18, 2022
    Assignee: Nutramax Laboratories, Inc.
    Inventors: Brian Cornblatt, Grace Cornblatt, Anton Bzhelyansky, Robert Henderson
  • Patent number: 10960057
    Abstract: The invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and a mushroom (preferably maitake, shiitake, or reishi mushroom) extract or powder. The invention also relates to the combination of sulforaphane or a derivative thereof and a mushroom (preferably maitake, shiitake, or reishi mushroom) extract or powder. The present invention also relates to the combination of a broccoli extract or powder and a mushroom (preferably maitake, shiitake, or reishi mushroom) extract or powder. The present provides compositions and methods relating to these combinations.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: March 30, 2021
    Assignee: NUTRAMAX LABORATORIES, INC.
    Inventors: Brian Cornblatt, Grace Cornblatt, Anton Bzhelyansky, Robert Henderson
  • Patent number: 10940130
    Abstract: An anxiolytic composition includes a synergistic combination of an L-theanine and a whey protein composition.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: March 9, 2021
    Assignee: NUTRAMAX LABORATORIES, INC.
    Inventors: Todd Henderson, David Griffin, David Bledsoe
  • Patent number: 10780077
    Abstract: The present invention relates to a composition for the protection, treatment and repair of cartilage in humans and animal joints. The composition contains a combination of unsaponifiable lipids together with one or more of polyphenols and/or catechins. The composition or kit may contain avocado:soybean unsaponifiables (ASU) and green tea.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: September 22, 2020
    Assignee: NUTRAMAX LABORATORIES, INC.
    Inventors: Todd R. Henderson, Louis Lippiello, Charles Filburn, David Griffin
  • Patent number: 10722524
    Abstract: Compositions are described including a synergistic combination of hydroxytyrosol and 3-O-acetyl-11-keto-?-boswellic acid. The hydroxytyrosol may be sourced from an olive extract and the 3-O-acetyl-11-keto-?-boswellic acid may be sourced from a Boswellia serrata extract. The compositions may be formulated for oral administration to a mammalian or an avian subject. Methods for treating, repairing, or reducing damage to connective tissue caused by one or more inflammatory mediators and for reducing levels of one or more inflammatory mediators in connective tissue are provided, the methods comprising orally administering the compositions to a subject in need thereof.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: July 28, 2020
    Assignee: NUTRAMAX LABORATORIES, INC.
    Inventors: Todd Henderson, David Griffin
  • Patent number: 10688158
    Abstract: The invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and a milk thistle extract or powder. The invention also relates to the combination of a sulforaphane or a derivative thereof and a milk thistle extract or powder. The invention also relates to the combination of a broccoli extract or powder and a milk thistle extract or powder. The invention provides compositions and methods relating to these combinations.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: June 23, 2020
    Assignee: NUTRAMAX LABORATORIES, INC.
    Inventors: Brian Cornblatt, Grace Cornblatt, Anton Bzhelyansky, Robert Henderson
  • Patent number: 10583178
    Abstract: The present disclosure relates to the synergistic combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, a cofactor of the enzyme, and a glucan. The present disclosure also relates to the synergistic combination of sulforaphane or a derivative thereof and a glucan. The present disclosure also relates to the synergistic combination of a broccoli extract or powder and a glucan. The glucan may be a ?-glucan. The glucan may be provided in a mushroom extract or powder selected from one or more of a maitake, a shiitake, or a reishi mushroom. Compositions and methods relating to these combinations are described.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: March 10, 2020
    Assignee: NUTRAMAX LABORATORIES, INC.
    Inventors: Brian Cornblatt, Grace Cornblatt, Anton Bzhelyansky, Robert Henderson
  • Patent number: 10485784
    Abstract: An orally administrable composition for treating or reducing damage to connective tissue or for treating or reducing inflammatory symptoms associated with damage to connective tissue includes a synergistic combination of: (i) avocado/soybean unsaponifiables; and (ii) lipoic acid, or a salt or derivative thereof. Methods for treating or reducing damage to connective tissue, for treating or reducing inflammatory symptoms associated with damage to connective tissue, or for reducing levels of one or more inflammatory mediators in connective tissue include administering the orally administrable composition to an avian or mammalian subject.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: November 26, 2019
    Assignee: NUTRAMAX LABORATORIES, INC.
    Inventors: Carmelita Frondoza, Todd R. Henderson, Reinhard Grzanna
  • Patent number: D926964
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: August 3, 2021
    Assignee: Nutramax Laboratories, Inc.
    Inventors: Brian Adams, David Griffin, Hubert Ratkowski
  • Patent number: D941457
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: January 18, 2022
    Assignee: Nutramax Laboratories, Inc.
    Inventors: Brian Adams, David Griffin, Hubert Ratkowski
  • Patent number: D941458
    Type: Grant
    Filed: August 11, 2020
    Date of Patent: January 18, 2022
    Assignee: Nutramax Laboratories, Inc.
    Inventors: Brian Adams, David Griffin, Hubert Ratkowski
  • Patent number: D941985
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: January 25, 2022
    Assignee: Nutramax Laboratories, Inc.
    Inventors: Brian Adams, David Griffin, Hubert Ratkowski
  • Patent number: D942609
    Type: Grant
    Filed: August 11, 2020
    Date of Patent: February 1, 2022
    Assignee: Nutramax Laboratories, Inc.
    Inventors: Brian Adams, David Griffin, Hubert Ratkowski